ST6GAL1

Across TCGA pan-cancer cohorts, ST6GAL1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ST6GAL1 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ST6GAL1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ST6GAL1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, GBM, and LUAD are the cancer types where ST6GAL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.719	0.429	<.001	28	view →
GBM	DFS	Median	All	0.277	0.443	.026	9	view →
LUAD	DFS	Quartile	All	0.852	0.504	.006	5	view →
LSCC	DFS	Quartile	II,III,IV	0.556	0.929	.026	2	view →
CCRCC	OS	Quartile	All	0.738	0.902	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ST6GAL1–PDAC (OS)

Open the PDAC breakdown →